8-K
filed April 2, 2025, 7:59 PM ET
ticker BGMS
CIK 0001130166
earnings
confidence high
sentiment negative
materiality 0.75
Cyclacel reports Q4 net loss $3.0M; pro forma cash $7.2M; deconsolidates unit; board appointments
Bio Green Med Solution, Inc.
2025-Q1 EPS reported
$0.00
- Net loss of $3.0M for Q4 2024 and $11.2M for full year; cash of $3.1M at Dec 31, 2024.
- Pro forma cash $7.2M including $4.1M equity financing post-quarter; cash runway into Q2 2025.
- Focusing on plogosertib (PLK1 inhibitor) acquired from Cyclacel Ltd; new oral formulation in development.
- Deconsolidation of Cyclacel Ltd expected to increase equity by ~$5.0M and significantly reduce R&D spend.
- Two new independent directors appointed: Inigo Angel Laurduraj and Dr. Satis Waran Nair Krishnan; committee chairs set.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Avraham Ben-Tzvi resigned as independent director at Bio Green Med Solution, Inc..
- Action
- resigned
- Role
- independent director
Exact text from the filing
on March 31, 2025, each of Avraham Ben-Tzvi and David Natan agreed to delay their previously announced resignation of their services to the Company as independent director from March 31, 2025 until the filing date of the Form 10-K. On such filing date, each of their resignation shall be automatically effective.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
David Lazar resigned as co-principal financial officer and co-principal accounting officer at Bio Green Med Solution, Inc..
- Action
- resigned
- Role
- co-principal financial officer and co-principal accounting officer
Exact text from the filing
On March 31, 2025, David Lazar, the Company’s co-principal financial officer and co-principal accounting officer agreed to delay his previously announced resignation from March 31, 2025 until the date that the Company’s annual report on Form 10-K for the fiscal year ended December 31, 2024 (the “Form 10-K”), is filed with the Securities and Exchange Commission (“SEC”). On such date, Mr. Lazar’s resignation shall be automatically effective.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Inigo Angel Laurduraj was appointed as independent director at Bio Green Med Solution, Inc..
- Action
- appointed
- Role
- independent director
Exact text from the filing
On April 2, 2025, coinciding with the effective time of the resignation of Messers. Ben-Tzvi and Natan, as independent directors, the Company appointed Ms. Inigo Angel Laurduraj and Dr. Satis Waran Nair Krishnan, as independent directors, on the Company’s board of directors (the “Board”) to fill the vacancies and to hold office until their successor shall have been duly elected and qualified or until her or his earlier death, resignation or removal.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
David Natan resigned as independent director at Bio Green Med Solution, Inc..
- Action
- resigned
- Role
- independent director
Exact text from the filing
on March 31, 2025, each of Avraham Ben-Tzvi and David Natan agreed to delay their previously announced resignation of their services to the Company as independent director from March 31, 2025 until the filing date of the Form 10-K. On such filing date, each of their resignation shall be automatically effective.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Satis Waran Nair Krishnan was appointed as independent director at Bio Green Med Solution, Inc..
- Action
- appointed
- Role
- independent director
Exact text from the filing
On April 2, 2025, coinciding with the effective time of the resignation of Messers. Ben-Tzvi and Natan, as independent directors, the Company appointed Ms. Inigo Angel Laurduraj and Dr. Satis Waran Nair Krishnan, as independent directors, on the Company’s board of directors (the “Board”) to fill the vacancies and to hold office until their successor shall have been duly elected and qualified or until her or his earlier death, resignation or removal.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.